| |
| |
|
| Insider
Information: |
Love Ted W |
| Relationship: |
Director |
| City: |
Sunnyvale |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
10 |
|
| Direct
Shares |
252,099 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,546,810 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
252,099 |
|
|
| Total
Value |
$2,546,810 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Nuvelo Inc |
ABIO |
Director |
2008-05-30 |
3,580 |
2004-02-27 |
0 |
Premium* |
|
|
Onyx Pharmaceuticals Inc |
ONXX |
EVP, R&D and Tech. Ope... |
2012-07-25 |
77,756 |
2010-02-01 |
0 |
Premium* |
|
|
Santarus Inc |
SNTS |
Director |
2014-01-02 |
0 |
2012-03-09 |
0 |
Premium* |
|
|
Amicus Therapeutics Inc |
FOLD |
Director |
2020-06-04 |
131,000 |
2014-03-12 |
0 |
Premium* |
|
|
Global Blood Therapeutics, Inc. |
GBT |
President and CEO, Dir... |
2022-10-05 |
0 |
2022-10-05 |
0 |
Premium* |
|
|
Cascadian Therapeutics, Inc |
CASC |
Director |
2018-03-09 |
0 |
2015-09-05 |
0 |
Premium* |
|
|
Portola Pharmaceuticals Inc |
PTLA |
Director |
2020-07-02 |
0 |
2019-09-18 |
0 |
Premium* |
|
|
Royalty Pharma Plc |
RPRX |
Director |
2023-06-23 |
36,941 |
|
0 |
Premium* |
|
|
Seagen Inc |
SGEN |
|
2023-12-14 |
0 |
2020-08-17 |
0 |
Premium* |
|
|
Gilead Sciences Inc |
GILD |
Director |
2024-05-08 |
2,822 |
2024-02-02 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SNTS |
Santarus Inc |
Director |
– • – |
2012-03-09 |
4 |
OE |
$1.18 |
$319,775 |
D/D |
150,500 |
150,500 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2015-09-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,341 |
17,341 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2016-06-06 |
5 |
OE |
$0.00 |
$0 |
D/D |
2,723 |
27,890 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2017-06-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,148 |
29,357 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2017-06-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,058 |
37,878 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
See Remarks |
• • – |
2017-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,062 |
1,156,489 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2017-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,375 |
37,988 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
See Remarks |
• • – |
2018-01-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,000 |
1,062,850 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
See Remarks |
• • – |
2018-01-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,000 |
1,080,767 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
See Remarks |
• • – |
2018-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,000 |
1,098,413 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
See Remarks |
• • – |
2018-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,063 |
1,093,123 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
See Remarks |
• • – |
2018-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,000 |
1,123,138 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
See Remarks |
• • – |
2018-07-16 |
4 |
OE |
$16.40 |
$199,982 |
D/D |
12,194 |
1,117,979 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
See Remarks |
• • – |
2018-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,812 |
1,139,791 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
See Remarks |
• • – |
2019-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,813 |
1,150,788 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
See Remarks |
• • – |
2019-04-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,000 |
1,178,553 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
See Remarks |
• • – |
2019-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,062 |
1,194,261 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
See Remarks |
• • – |
2019-12-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
87,500 |
1,185,367 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
See Remarks |
• • – |
2020-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,063 |
1,095,626 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
See Remarks |
• • – |
2020-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
42,017 |
770,650 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
President and CEO |
• • – |
2021-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
42,018 |
791,834 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
President and CEO |
• • – |
2021-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,955 |
804,266 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
President and CEO |
• • – |
2021-09-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,444 |
798,857 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
President and CEO |
• • – |
2022-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,955 |
799,308 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
President and CEO |
• • – |
2022-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,445 |
799,061 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
